Cargando…

New dual peroxisome proliferator activated receptor agonist—Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence

BACKGROUND: Saroglitazar, a novel dual peroxisome proliferator activated receptor (PPAR) agonist, in clinical trials, has shown an improvement in lipid and glycemic parameters through the PPAR-α and γ agonist actions, respectively. It was granted marketing authorization in India in 2013 for diabetic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaul, Upendra, Parmar, Deven, Manjunath, K., Shah, Mitesh, Parmar, Krupi, Patil, Kishor P., Jaiswal, Ashok
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580520/ https://www.ncbi.nlm.nih.gov/pubmed/31208414 http://dx.doi.org/10.1186/s12933-019-0884-3

Ejemplares similares

Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study)
por: Krishnappa, Manjunath, et al.
Publicado: (2020)

Saroglitazar is noninferior to fenofibrate in reducing triglyceride levels in hypertriglyceridemic patients in a randomized clinical trial
por: Rodriguez-Gutierrez, Rene, et al.
Publicado: (2022)

Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study
por: Goyal, Omesh, et al.
Publicado: (2020)

A Multicenter, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Saroglitazar in Patients With Primary Biliary Cholangitis
por: Vuppalanchi, Raj, et al.
Publicado: (2021)

Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models
por: Jain, Mukul R., et al.
Publicado: (2017)

Significant Reduction of Elevated Triglycerides and Liver Fibrosis in Diabetic Dyslipidemia with Saroglitazar: A Case Report
por: Roy, Sayak, et al.
Publicado: (2019)

Efficacy and safety of saroglitazar for the management of dyslipidemia: A systematic review and meta-analysis of interventional studies
por: Chhabra, Manik, et al.
Publicado: (2022)

The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease
por: Kumar, Divya P., et al.
Publicado: (2020)

Saroglitazar in Non-alcoholic Fatty Liver Disease From Bench to Bedside: A Comprehensive Review and Sub-group Meta-Analysis
por: Roy, Akash, et al.
Publicado: (2023)

Pharmacokinetics, Safety, and Tolerability of Saroglitazar (ZYH1), a Predominantly PPARα Agonist with Moderate PPARγ Agonist Activity in Healthy Human Subjects
por: Jani, Rajendra H., et al.
Publicado: (2013)

Saroglitazar – A Potential Therapeutic Option in Treating NASH? [Letter]
por: Shuja, Syed Hasan, et al.
Publicado: (2021)

Clinical Case Series of Decrease in Shear Wave Elastography Values in Ten Diabetic Dyslipidemia Patients Having NAFLD with Saroglitazar 4 mg: An Indian Experience
por: Roy, Sayak
Publicado: (2020)

Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis
por: Akbari, Rasoul, et al.
Publicado: (2021)

Effect of herbal extracts and Saroglitazar on high-fat diet-induced obesity, insulin resistance, dyslipidemia, and hepatic lipidome in C57BL/6J mice
por: Kumari, Deepika, et al.
Publicado: (2023)

Efficacy and safety of saroglitazar in real‐world patients of non‐alcoholic fatty liver disease with or without diabetes including compensated cirrhosis: A tertiary care center experience
por: Chaudhuri, Sujit, et al.
Publicado: (2023)

Saroglitazar for the treatment of hypertrig-lyceridemia in patients with type 2 diabetes: current evidence
por: Sosale, Aravind, et al.
Publicado: (2015)

A Multicenter, Prospective, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared to Pioglitazone 45 mg in Diabetic Dyslipidemia (PRESS V)
por: Pai, Vikas, et al.
Publicado: (2014)

Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease
por: Martin, Anna, et al.
Publicado: (2022)

Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models
por: Jain, Mukul R, et al.
Publicado: (2015)

A Contemporary Overview of PPARα/γ Dual Agonists for the Management of Diabetic Dyslipidemia
por: Balakumar, Pitchai, et al.
Publicado: (2019)

The isolation, Characterization and Preclinical Studies of Metal Complex of Thespesia populnea for the Potential Peroxisome Proliferator-activated Receptors-γ Agonist Activity
por: Phanse, Mohini Ashok, et al.
Publicado: (2015)

Deciphering the Precise Target for Saroglitazar Associated Antiangiogenic Effect: A Computational Synergistic Approach
por: Dabral, Swarna, et al.
Publicado: (2023)

Observational Study of Effects of Saroglitazar on Glycaemic and Lipid Parameters on Indian Patients with Type 2 Diabetes
por: Chatterjee, Sanjay, et al.
Publicado: (2015)

An Observational Study of Reduction in Glycemic Parameters and Liver Stiffness by Saroglitazar 4 mg in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
por: Mitra, Asis
Publicado: (2020)

Comparison of the relationships of alcoholic and nonalcoholic fatty liver with hypertension, diabetes mellitus, and dyslipidemia
por: Toshikuni, Nobuyuki, et al.
Publicado: (2013)

Dual targeting of peroxisomal proteins
por: Ast, Julia, et al.
Publicado: (2013)

Atherogenic dyslipidemia
por: Manjunath, C. N., et al.
Publicado: (2013)

New perspective on type 2 diabetes, dyslipidemia and non‐alcoholic fatty liver disease
por: Matsuzaka, Takashi, et al.
Publicado: (2020)

Pathway Compartmentalization in Peroxisome of Saccharomyces cerevisiae to Produce Versatile Medium Chain Fatty Alcohols
por: Sheng, Jiayuan, et al.
Publicado: (2016)

Peroxisomal metabolic coupling improves fatty alcohol production from sole methanol in yeast
por: Zhai, Xiaoxin, et al.
Publicado: (2023)

Dyslipidemia in Dermatological Disorders
por: Shenoy, Chetana, et al.
Publicado: (2015)

Are fish oil omega-3 long-chain fatty acids and their derivatives peroxisome proliferator-activated receptor agonists?
por: Gani, Osman ABSM
Publicado: (2008)

Dual PPRαϒ Agonists for the Management of Dyslipidemia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
por: Menezes Junior, Antonio da Silva, et al.
Publicado: (2023)

Associations of Fatty Liver Disease with Hypertension, Diabetes, and Dyslipidemia: Comparison between Alcoholic and Nonalcoholic Steatohepatitis
por: Toshikuni, Nobuyuki, et al.
Publicado: (2017)

Impact of thyroid cancer on the cancer risk in patients with non-alcoholic fatty liver disease or dyslipidemia
por: Ho, Joon, et al.
Publicado: (2023)

A role of peroxisome proliferator‐activated receptor γ in non‐alcoholic fatty liver disease
por: Skat‐Rørdam, Josephine, et al.
Publicado: (2019)

Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers
por: Kansagra, Kevinkumar A., et al.
Publicado: (2017)

Transplacental induction of fatty acid oxidation in term fetal pigs by the peroxisome proliferator-activated receptor alpha agonist clofibrate
por: Lin, Xi, et al.
Publicado: (2015)

The Renoprotective Actions of Peroxisome Proliferator-Activated Receptors Agonists in Diabetes
por: Thomas, M. C., et al.
Publicado: (2012)

The Agonists of Peroxisome Proliferator-Activated Receptor-γ for Liver Fibrosis
por: Li, Jingjing, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1aplhlt1eta0kbh9aojr8b02a3